Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Cash from Investing Activities (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Cash from Investing Activities for 3 consecutive years, with -$7000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Investing Activities rose 97.17% to -$7000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$44000.0, a 99.27% increase, with the full-year FY2024 number at -$2.6 million, up 43.46% from a year prior.
  • Cash from Investing Activities was -$7000.0 for Q3 2025 at Inhibrx Biosciences, up from -$21000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of -$7000.0 in Q3 2025 to a low of -$3.4 million in Q4 2023.
  • A 3-year average of -$859750.0 and a median of -$529000.0 in 2023 define the central range for Cash from Investing Activities.
  • Biggest YoY gain for Cash from Investing Activities was 99.54% in 2024; the steepest drop was 69.54% in 2024.
  • Inhibrx Biosciences' Cash from Investing Activities stood at -$3.4 million in 2023, then skyrocketed by 99.54% to -$16000.0 in 2024, then skyrocketed by 56.25% to -$7000.0 in 2025.
  • Per Business Quant, the three most recent readings for INBX's Cash from Investing Activities are -$7000.0 (Q3 2025), -$21000.0 (Q1 2025), and -$16000.0 (Q4 2024).